Correlation of blood cell counts with mutant subtypes and impact prognosis in acute myeloid leukemia patients with FLT3 mutations

References

• Rosnet O, Mattei MG, Marchetto S, et al. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics. 1991;9(2):380–385.
   PubMed Web of Science ®Google Scholar
• Agnes F, Shamoon B, Dina C, et al. Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene. 1994;145:283–288.
   PubMed Web of Science ®Google Scholar
• Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114:2386–2392.
   PubMed Web of Science ®Google Scholar
• Chatain N, Perera RC, Rossetti G, et al. Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine. Leukemia. 2015;29:2434–2438.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–2221.
   PubMed Web of Science ®Google Scholar
• Naseem S, Binota J, Varma N, et al. NPM1 and FLT3-ITD/TKD gene mutations in acute myeloid leukemia. Int J Hematol Oncol Stem Cell Res. 2021;15(1):15–26.
   PubMedGoogle Scholar
• Liu SB, Qiu QC, Bao XB, et al. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. Cancer Sci. 2018;109(12):3981–3992.
   PubMed Web of Science ®Google Scholar
• Zhao JC, Agarwal S, Ahmad H, et al. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52:100905.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Richard FS, Sabine K, Lars B, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124:3441–3449.
   PubMed Web of Science ®Google Scholar
• Zhao S, Pan H, Guo Q, et al. Platelet to white blood cell ratio was an independent prognostic predictor in acute myeloid leukemia. Hematology. 2022;27(1):426–430.
   PubMed Web of Science ®Google Scholar
• Carow CE, Levenstein M, Kaufmann SH, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood. 1996;87:1089–1096.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752–1759.
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020 Feb;111(2):312–322.
   PubMed Web of Science ®Google Scholar
• Halahleh K, Taqash A, Abdelkhaleq H, et al. Analysis of FLT3-activating mutations in patients with acute myelogenous leukemia in Jordan: association with FAB subtypes and identification of subgroups with poor prognosis. Clin Lymphoma Myeloma Leuk. 2021;21(7):e588–e597.
   PubMed Web of Science ®Google Scholar
• Abou Dalle I, Ghorab A, Patel K, et al. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J. 2020;10(5):48.
   PubMed Web of Science ®Google Scholar
• Liu SB, Dong HJ, Bao XB, et al. Impact of FLT3-ITD length on prognosis of acute myeloid leukemia. Haematologica. 2019;104(1):e9–e12.
   PubMed Web of Science ®Google Scholar
• Medinger M, Passweg JR. Acute myeloid leukaemia genomics. Br J Haematol. 2017;179(4):530–542.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Paschka P, Späth D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol. 2012;30(12):1350–1357.
   PubMed Web of Science ®Google Scholar
• Cher CY, Leung GMK, Au CH, et al. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome. Blood Cancer J. 2016;6(7):e442.
   PubMedGoogle Scholar
• Fathi A T, Perl A E, Levis M, et al. Concurrent FLT3 inhibitor and IDH inhibitor therapy in patients with Acute Myeloid Leukemia (AML). Blood. 2020;136(Supplement 1):11–12.
   PubMedGoogle Scholar
• Garciaz S, Hospital M A, Saillard C, et al. IDH mutations identify a subgroup of NPM1 patients with a more favorable prognosis. a retrospective multicenter study of the filo group. Blood. 2020;136(Supplement 1):39–40.
   Google Scholar
• Guan W, Zhou L, Li Y, et al. Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns. Exp Hematol Oncol. 2021;10(1):27.
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–1089.
   PubMed Web of Science ®Google Scholar
• Chen F, Sun J, Yin C, et al. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation. Bone Marrow Transplant. 2020;55(4):740–748.
   PubMed Web of Science ®Google Scholar